Skip to Main content Skip to Navigation
Theses

Synthesis, physicochemical and biological evaluation studies of ruthenium(II) and osmium(II) anticancer organometallic complexes

Abstract : Since the clinical success of platinum drugs (cisplatin and its derivatives) as anticancer agent, medicinal inorganic chemistry has become a field of growing interest because it offers an alternative for the design of therapeutic agents that are not readily available to organic compounds. Although cisplatin is one of the most widely used drugs in chemotherapy, it is not effective for all types of cancer. Moreover, platinum drugs are the cause of disabling side effects (neurotoxicity, nephrotoxicity, weight loss, nausea…) and their applicability is limited by innate or induced resistance to platinum in a narrow range of tumours. Therefore, this clinical success has promoted the search for cytotoxic compounds with enhanced activities and more acceptable toxicity profiles. This has stimulated interest in complexes containing other heavy metals of the platinum group such as ruthenium because these compounds show lower toxicity than drugs based on platinum. Some ruthenium compounds have already shown promising anticancer activity and two RuIII complexes trans-[RuCl4-(DMSO)(Im)]ImH (NAMI-A and trans-[RuCl4(Ind)2]IndH (KP1019) recently enter in clinical phase for their respectively antimetastatic and cytotoxic properties.In the essential aim of increasing activity and reducing side effects of anticancer agents, the Laboratoire de Synthèses Métallo-Induites has developed for several years organometallic ruthenium compounds RDC (Ruthenium Derivative Compound) in which one of the ligand is strongly bound to the metal via a strong σ C-Ru bond and stabilized by an intramolecular N-Ru bond. This thesis presents the recent advances of the laboratory in this field and the development of a second generation RDC in which the cylometallating ligand is stabilized by two N-Ru bonds. Thus, several complexes pass the symbolic barrier of the nanomolar range for their IC50 indicating a critical improvement. At the same time, we decided to focus our studies on osmium heavier congener, not only to complete the RDC chemical library, but also to verify the impact of exchanging the metal. An extensive chemical library ODC (Osmium Derivative Compound) of forty cyclometalated osmium complexes was synthesized and evaluated in vitro. Biological studies on these ODCs showed that osmium is another metal that deserves attention for the development of new effective antitumour drugs. The measurements of physicochemical properties such as red-ox potential and lipophylicity (log(Po/w)) allowed us to tentatively correlate these parameters to the level of activity, thus approaching a possible Property-Activity Relationship (P.A.R.). More insight into the role of the red-ox potential will probably become clearer as we progress into the mechanism of action of these species.
Document type :
Theses
Complete list of metadatas

https://tel.archives-ouvertes.fr/tel-00796216
Contributor : Abes Star :  Contact
Submitted on : Saturday, March 2, 2013 - 1:04:52 AM
Last modification on : Thursday, July 19, 2018 - 12:15:18 PM
Long-term archiving on: : Sunday, April 2, 2017 - 8:24:31 AM

File

BOFF_Bastien_2012_ED222.pdf
Version validated by the jury (STAR)

Identifiers

  • HAL Id : tel-00796216, version 1

Collections

Citation

Bastien Boff. Synthesis, physicochemical and biological evaluation studies of ruthenium(II) and osmium(II) anticancer organometallic complexes. Other. Université de Strasbourg, 2012. English. ⟨NNT : 2012STRAF001⟩. ⟨tel-00796216⟩

Share

Metrics

Record views

599

Files downloads

949